Seattle Genetics Highlights Adcetris Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive Malignancies from Multiple Presentations at ASH Annual Meeting -Investigator Analysis Shows Median Overall Survival for ADCETRIS-Treated Relapsed HL Patients after ASCT Was 91 Months Compared with 28 Months among Non-ADCETRIS Patients- -ADCETRIS Activity ... (more)
http://www.drugs.com/clinical_trials/seattle-genetics-highlights-adcetris-brentuximab-vedotin-data-relapsed-hodgkin-lymphoma-other-cd30-14856.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29
http://www.drugs.com/clinical_trials/seattle-genetics-highlights-adcetris-brentuximab-vedotin-data-relapsed-hodgkin-lymphoma-other-cd30-14856.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29
No comments:
Post a Comment